Kornimate/medical-research-clean huggingface dataset:
covid-19: a scope research on epidemiology and clinical course

Conditions: Covid19; SARS CoV 2 Infection; Sequelae of; Infection

Summary: severe acute respiratory syndrome (sars) coronavirus (cov) 2 infection and the associated coronavirus disease 2019 (covid-19) are the most recent international health threat challenging our ability to protect populations, to avoid severe outcomes and to understand both the population dynamics of this new condition and the breath of individual responses. gathering information on the clinical course of the disease and the risk of transmission is essential to design effective therapeutic solutions and preventive measures. the aim of the study proposed, to be carried out at university hospital center of "são joão" (chusj), is to recruit and follow-up a cohort of patients diagnosed with sars-cov-2 infection, to evaluate the clinical course of sars-cov-2 infection and covid-19 cases, to identify prognostic factors and to measure the risk of reinfection. additionally, researchers intend to characterize the patients and household contacts to describe the dynamics of infection, to calculate household infection attack rate, and to perform the genetic sequencing of sars-cov-2 to understand determinants of disease course (namely long-term effects) and risk of household transmission. a sample of participants, identified during the process of evaluation of symptomatic individuals, at the same institution, and negative for sars-cov-2 will be selected as negative controls. participants will be consecutively recruited and the study is expected to enroll patients as long as the pandemic remains. information will be gathered based on clinical individual charts, hospital data-bases (example: for administrative data) and individual computer assisted interviews to be performed at pre-defined intervals (3, 12 and 24 months) or according to clinical needs. the project was approved by the local ethical committee and the data protection relevant authorities.


Eligibility criteria:
inclusion criteria: * individuals diagnosed with sars-2-cov-2 infection treated at chusj and cohabitants able to give informed consent; * individuals who underwent the test for diagnosis of infection by sars-cov-2 at chusj with negative result able to give informed consent. exclusion criteria: * inability to obtain informed consent;

Keywords: covid19 cohort studies long covid secondary attack rate serology epidemiology
hbot effect on chronic pain syndrome with a history of psychological trauma

Conditions: Fibromyalgia; Chronic Pain Syndrome

Summary: the aim of the study is to evaluate the effect of hyperbaric oxygen therapy (hbot) on 2 types of patients' population suffering from chronic pain syndrome (fibromyalgia): patients with history of psychological trauma and patients with history of traumatic brain injury.

this study is a prospective clinical trial. after signing a written informed consent, all patients will be invited to medical evaluation including pain sensitivity examination and a series of questionnaires. in addition, all patients will have chest x-ray, cognitive evaluation, brain mri and brain single-photon emission computed tomography (spect) . a second brain mri, brain spect, pain sensitivity evaluation and questionnaires will be done after 3 months of treatment (60 sessions of hbot). the hbot procedure will be performed at the sagol center for hyperbaric medicine and research of assaf harofeh medical center, israel. the following hbot protocol will be applied for all patients: 12 weeks, 5 times per week, daily administration of 100% o2 for 90 minutes at a pressure of 2 absolute atmospheres (ata) including 5 minutes air breaks every 30 minutes. patients with history of psychological trauma are also being treated with creative art psychotherapy. these patients will be randomly assigned to one of the two groups: (1) single intervention with creative art psychotherapy (psychotherapy group); (2) combined concurrent intervention of hbot and creative art psychotherapy. groups 1 will serve as controls during the first 3 months and then will be crossed to get hbot. before the cross to the hbot they will have 2nd full evaluation (questioners and brain imaging).

Eligibility criteria:
inclusion criteria: * females * age over 18 * known fibromyalgia (chronic pain syndrome) for more than 1 year exclusion criteria: * any past hyperbaric treatment prior to inclusion * patients with chest x-ray pathology incompatible with hyperbaric environment * patients with middle ear problems * patients, who cannot "pump", equals middle ear pressure, effectively * patients who suffer from claustrophobia * inability or refusing to sign the informed consent form

Keywords: more than 1 year
biological and cognitive marker of neurodegeneration in obstructive sleep apnea patients

Conditions: Sleep Apnea, Obstructive

Summary: the goal of this observational study is to investigate biomarkers and neurocognitive markers of neurodegenerative processes in obstructive sleep apnea patients. the main questions the study aims to answer are: * does neurodegeneration assessed by neurobiological markers and neurocognitive test performance exists in obstructive sleep apnea? * are these neurodegenerative markers are associated with the adherence to clinical prescribed positive airway pressure therapy? newly diagnosed patients with obstructive sleep apnea will be observed during the use of clinical prescribed positive pressure therapy. different study related investigations take place before and six months after treatment start. researchers will compare after six months the group of adherent treatment participants with the non-adherent treatment participants group to investigate if differences in the observed neurobiological or neurocognitive parameters exist.


Eligibility criteria:
inclusion criteria: * newly diagnosed obstructive sleep apnea * clinical indication for start of positive airwas pressure therapy * age older than 18 years exclusion criteria: * neurodegenerative disease * multiple sclerosis * stroke within last 3 months * brain injury within last 3 months * moca \&lt; 21 points * higher degree chonic kidney disease (lower than 30 ml/min) * regular use of sleep pills (e.g. zopiclon, mirtazapin, daridorexant)

Keywords: sleep apnea neurodegeneration neurofilament light chain glial fibrillary acidic protein positive airway pressure therapy
effectiveness and safety of rhubarb for the treatment of patients who have suffered from a stroke

Conditions: Pneumonia; Acute Stroke

Summary: this study will determine if rhubarb will reduced the incidence of pneumonia and improved recovery from an acute stroke. the study is designed to look at both infection rate and overall recovery and recovery of motor function, for example muscle strength and coordination.


Eligibility criteria:
inclusion criteria: * occurrence of an acute ischemic stroke (between 9 and 72 h after onset) with a score of at least 6 on the national institute of health stroke scale (nihss), and patient age of at least 18 years. * have no pneumonia according to modified criteria of the u.s. centers for disease control and prevention (cdc) * consistent with the constipation of phlegm-heat accumulation type by traditional chinese medicine (tcm) standard * patients or their representatives voluntarily take part in this study and signed the informed consent exclusion criteria: * cerebral hemorrhage, subarachnoid hemorrhage * transient ischemic attack(tia) * proven cerebral embolism caused by tumor, brain trauma, cerebral parasitic disease, dysbolismus, fibrillation atrial resulted from rheumatic heart disease, coronary heart disease, and other heart diseases * clinical signs of infection on admission * pregnant or breast-feeding * allergic to rhubarb * preceding or ongoing antibiotic therapy within the last 24 h * participation in another interventional trial * immunosuppressant treatment within the last 30 days * combining severe clinical conditions such as liver, kidney, hematopoietic system, endocrine system or psychological diseases

Keywords: lung infection after ischemic stroke prevention of pneumonia rhubarb
the nordic aortic valve intervention trial 4 (notion-4)

Conditions: Aortic Valve Stenosis; Cardiovascular Diseases; Heart Diseases; Heart Valve Diseases; Valve Disease, Aortic

Summary: a randomized clinical trial investigating the incidence and temporal dynamics of subclinical leaflet thickening by cardiac ct in transcatheter bioprosthetic aortic valves in patients randomised to different anti-thrombotic strategies. additionally, this study aims to examine a possible association between halt and thromboembolic events.

the notion-4 trial is an investigator-initiated, randomized, open label, comparative trial conducted at rigshospitalet in copenhagen and skejby sygehus in aarhus. all adult patients that have undergone successful tavi without contraindications for cardiac ct will be invited to participate in this study. patients with sr and without known other indication for chronic oac therapy will be randomized 1:1 either to lifelong asa or to 3 months of doac followed by lifelong asa. patients with known af will be randomized 1:1 to lifelong doac versus laac within 3 months followed by lifelong asa.

Eligibility criteria:
inclusion criteria: * patients who underwent successful tavi according to valve academic research consortium (varc)-2 criteria * residing in denmark * provided written informed consent exclusion criteria: * atrial fibrillation or any other indication for lifelong oral anticoagulant therapy * patient deemed not suitable for doac treatment because of previous life-threatening or major bleeding, e.g. intracranial haemorrhage or major gastrointestinal bleeding * patients with severe renal insufficiency (egfr \<30 ml/min/1.73 m2) * patient with absolute indication for anti-thrombotic therapy, e.g. recent pci * iodine contrast allergy or other condition that prohibits ct imaging * age \<18 years * women of childbearing potential, pregnant or nursing

Keywords: heart valve disease valvular bioprosthesis aortic valve replacement randomized clinical trial tavi antitrombotic medication
tumor markers in lung cancer

Conditions: Lung Cancer

Summary: the aim of this study is to determine if dcamlk1 can be measured in the endobronchial biopsy specimens and bronchial washings from patients with lung cancer.

dcamlk1 is a ca2+ - ca/modulin (cam) - dependent protein kinase that is a marker of stem cells in colonic crypts. mutations within the stem cell population are thought to be responsible for the development of most colorectal carcinomas and studies have shown that dcamlk1 is highly expressed in these tumors. since the lung is an embryological development of the foregut, we speculate that dcamlk1 will also be upregulated in lung cancers. the aim of this pilot study is to determine if dcamlk1 can be measured in the endobronchial biopsy specimens and bronchial washings from patients with lung cancer. this is a prospective study in 10 patients with lung masses suspected to be malignant who are scheduled for diagnostic bronchoscopy. patients with lung masses scheduled for diagnostic bronchoscopy will be included if they can give informed consent to participate and the diagnostic portion of the bronchoscopy has been uncomplicated. patients considered to be at high risk during bronchoscopy because of either abnormal blood gases (pco2 \> 50 mmhg or pao2 \ 1.5) will be excluded. if the preliminary results indicate this is feasible, we will then propose a larger study to examine dcamlk1 distribution in normal and cancerous tissue as well as the predictive value of this biomarker.

Eligibility criteria:
inclusion criteria: * abnormality on chest x-ray that requires diagnosis and physically capable of undergoing bronchoscopy exclusion criteria: * \<45 years * patients with severe abnormalities in blood gases and/or a coagulopathy will be excluded.
hypotension prediction index to predict epidural-labor analgesia induced hypotension

Conditions: Anesthesia, Epidural; Hypotension

Summary: the purpose of this pilot trial is to examine the feasibility and ease of use of monitoring by clearsight in laboring and delivering patients with the intent to compare time-to-treatment of hypotension between conventionally monitored patients (group cm) and those receiving hpi (group cm + hpi) monitoring by clearsight, in a population of healthy laboring women who receive epidural analgesia.

in a prospective study, we will achieve the following aims: to determine the feasibility and ease of use of the clearsight monitoring system in the labor-delivery room (ldr) in detecting and monitoring hypotensive events post-epidural labor analgesia placement. to compare the time-to-treatment of hypotensive events between the conventionally monitored patients (group cm) and those receiving hpi (group cm + hpi) monitoring by clearsight.

Eligibility criteria:
inclusion criteria: * pregnant * age ≥ 18 years of age. * receiving epidural labor analgesia (ela) exclusion criteria: * non-reassuring fetal tracing at the time of ela request * contraindications to ela * significant cardiac arrhythmias or aortic regurgitation * arrhythmia * treatment with antihypertensive medications * pre-eclampsia with or without severe features * preoperative infection * inability to use clearsight device for any reason * incomplete data
long-term effect of a 3-month supplementation with holo-blg on house dust mite induced allergic rhinoconjunctivitis

Conditions: Dust Mite Allergy; Allergic Rhinitis

Summary: the aim of the study is to investigate the long-term effect of a lozenge containing beta-lactoglobulin (blg), iron, retinoic acid, zinc and polyphenols (holo-blg) in people with allergic rhinoconjunctivitis caused by house dust mites and the associated symptoms (symptom type and severity) during exposure to house dust mites in an allergen exposure chamber (aec). in particular, the study aims to evaluate whether the improvements in symptoms of house dust mite-induced rhinoconjunctivitis observed after 3 months of supplementation with holo-blg can still be detected 7 to 8 months after the last intake.


Eligibility criteria:
inclusion criteria: * participation in the predecessor study including complete intake of the holo-blg lozenge for 3 months; inclusion in the final analysis set of the predecessor study * patients with allergic rhinoconjunctivitis caused by house dust mites of any gender, aged 18-65 years * verbal and written informed consent exclusion criteria: * persons \<18 years * lack of verbal and written consent * persons who do not speak german * seriously ill persons * persons with immunosuppressive medication such as systemic corticosteroids, cyclosporine * pregnancy and breastfeeding * psychiatric illness * persons who have received or have started sublingual or subcutaneous immunotherapy (slit/scit) against house dust mites in the last 2 years before screening * contraindications and/or history of adrenaline intolerance and/or emergency medication. * concurrent use of anti-allergic medications and/or inadequate washout period of these anti-allergic medications prior to the selection process and exposure in the exposure chamber * use of an investigational drug 30 days/5 half-lives of the drug (whichever is longer) prior to screening * use of certain drugs prior to v5: systemic corticosteroids within 3 weeks; topical nasal corticosteroids within 2 weeks; chromones within 7 days; antihistamines within 72h; antibiotics within 3 months; pro-, pre- and synbiotics 1 month
iron supplementation outcome on recurrent upper respiratory tract infections in 6-15 years old egyptian school children

Conditions: Recurrent Upper Respiratory Tract Infections; Iron Deficiency Anemia

Summary: recurrent upper respiratory infections ( rurtis) are common in school aged children. an adequate iron status might reduce their prevalence. the aim of the study is to assess the percentage and type of rurtis in egyptian school children, assessing the percentage of iron deficiency anemia (ida) and the effect of iron supplementation on the recurrence and severity of upper respiratory tract infections .

this is a prospective interventional study in which 1000 children (6-15 years) are recruited from two schools in urban cairo; three months enrollment was done in early autumn ; students defined to have rurtis were screened by hemocue; if anemic (hb \< 11.5gm/dl),complete blood picture and iron profile were done, they were enrolled into 2 groups: (a)children with ida on oral iron fumerate therapy (6mg/kg/d) for 3 months, then maintained on oral iron (1mg/kg/d) for 12 months, and (b) non anemic group; were randomly assigned in 1:1 ratio into: group (b1)children received maintenance iron therapy for 12 months and group (b2) received placebo. recurrence and severity of urtis using (carifs score) throughout the study are recorded

Eligibility criteria:
inclusion criteria: * both genders were eligible, and we did not seek to balance the number of boys and girls. * children completed the compulsory vaccination schedule of egypt. exclusion criteria: * children with coexisting chronic disease such as renal, hepatic failure , iddm, endocrine diseases, bronchial asthma and chronic diarrhea . * patients with suspected immunodeficiency by presence of some of the warning symptoms or signs .

Keywords: iron rurtis carifs children
a prospective study: sintilimab and r-chop in pmbcl treatment

Conditions: Primary Mediastinal Large B Cell Lymphoma

Summary: the purpose of this multi-center, single arm, phase ⅱ clinical trail is to evaluate the efficacy and toxicity of sintilimab combined with r-chop regimen as first-line treatment for primary mediastinal large b-cell lymphoma (pmbcl)


Eligibility criteria:
inclusion criteria: * pathological diagnosis of pmbcl , and did not receive any previous treatment for pmbcl ; * predicted survival time ≥ 6 months ; * 18-75 years ; * ipi score 0-3； * ecog performance status 0-2 ; * clinicians judge that the patient is suitable for the treatment of primary mediastinal large b-cell lymphoma ; * after the patient was enrolled in the trial, other drugs that may have therapeutic effects on primary mediastinal large b-cell lymphoma were not acceptable ; * wbc ≥ 3 × 109 / l, ne ≥ 1.5 × 109 / l, plt ≥ 100 × 109 / l ; * serum creatinine ≤ 1.5mg / dl, creatinine clearance rate ≥ 50ml / min ; * alt, ast ≤ 3 × uln ( normal upper limit ) ; total bilirubin ≤ 2 × uln ; * sign the informed consent. exclusion criteria: * other malignant diseases except pmbcl were diagnosed within 5 years；·participating in other interventional clinical studies, or has received chemotherapy, radiotherapy, immunotherapy or biotherapy for lymphoma； * known allergies to test drugs or any excipient component of these products；·allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation has been performed； * women in pregnancy or lactation； * severe infectious diseases, such as hiv infection, untreated active hepatitis b, active hepatitis c； * the researchers believe that there are other potential risks that are not suitable for participation in this study.

Keywords: primary mediastinal large b cell lymphoma sintilimab r-chop
evaluating surface area reduction using moleculight imaging device

Conditions: Wound; Wound Infection

Summary: 12-week single-blind, prospective, randomized, controlled, pilot clinical trial assessing the moleculight i:x imaging device in chronic wounds. this device guides clinicians to inspect, sample, debride or further evaluate areas within or around a wound where potentially harmful bacteria appear under violet light illumination resulting in better overall care and accelerated surface area reduction compared to current standard care. the study aims to determine if this device aids in the healing of chronic wounds by reduction in size of wound compared to current standard of care.

this is a prospective, 12-week, single-blinded, randomized, controlled clinical trial has been designed with two primary objectives needed to inform more comprehensive studies at a later date. we propose to evaluate the following two primary outcomes: (1) the ability of the moleculight i:x imaging device to predict non healing wounds and wounds at risk or infection (control arm) and (2) whether utilization of the moleculight i:x imaging device in guiding clinicians to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present (treatment arm) increases wound healing rates relative to standard care (control arm) for the treatment of chronic wounds. both arms will receive standard procedures associated with wound care (e.g., sampling, debridement, preventative care, infection control, etc.) according to best practice guidelines. patients will be randomly assigned to either the control or treatment arm and be followed as per the study protocol every time their wound is cared for over a 12-week period. the effectiveness of the moleculight i:x imaging device will be assessed with evaluation of wound surface area reduction rate and infection rates (incidence of infection and time to eradicate infection) compared to standard care. all subjects randomized will be evaluated for 12 weeks from the date of enrollment and treatment initiation. subjects who may have wound closure within the 12-week study period will continue to have scheduled study evaluation visits up to the end of week 12.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years 2. having a chronic wound that is not a diabetic foot ulcer 3. presence of the wound for ≥ 6 weeks and ≤ 2 years. 4. wound size surface area ≥ 2 cm2 and ≤ 50 cm2. 5. willingness to comply with prescribed wound care regimen exclusion criteria: 1. candidate for surgery in the next 12 weeks 2. a wound with necrotic tissue unable to tolerate debridement 3. uncontrolled diabetics (defined as hba1c of \>85.5mmol/mol) 4. presence of a diabetic foot ulcer 5. currently taking medication that may interfere with wound healing (e.g., oral systemic steroids, immunosuppressive drugs, unfractionated heparin infusion) 6. women who are currently pregnant or are breast feeding; or women of child bearing potential who are not currently taking adequate birth control 7. participation in another investigative drug or device trial currently or within the last 30 days